Direct-to-consumer digital care firm Hims & Hers is the newest digital well being firm to announce it’s going to add GLP-1 medication to its merchandise to assist customers handle weight reduction.
The San Francisco-based firm, which launched the load loss program in December, mentioned customers can now get generic and 503B compound injectable medication for weight administration, in addition to oral remedy kits, beginning at $199 monthly.
The corporate mentioned in an announcement that its drug can be extra accessible than manufacturers like Ozempic or Wegovy due to a partnership with a U.S. generic GLP-1 producer.
“We leverage our dimension and scale to safe entry to one of many highest high quality compounded GLP-1 injectable provides obtainable at the moment. We’re delivering this chance and worth to our prospects who deserve the very best medical security requirements,” Hims & Hers Chief CEO and co-founder Andrew Dudum mentioned in an announcement:
bigger pattern
Researchers proceed to guage the security of long-term use of GLP-1 medication.
A examine revealed in The Worldwide Journal of Medical Pharmacy revealed that increasingly information present that GLP-1 receptor agonists are associated to pancreatic most cancers.
Nonetheless, one other examine revealed in JAMA Community Open reveals that researchers discovered no proof of an elevated incidence of pancreatic most cancers seven years after beginning GLP-1 remedy.
Different firms which have added GLP-1-focused merchandise to their platforms embrace Digital Persistent Illness Administration Bailing Well being.
Digital Weight Loss Firm Noom introduced that its business enterprise, Noom for Work, and nationwide pharmacy profit supervisor Liviniti are collaborating to supply plan sponsors and their workers with a digital GLP-1 Companion for power weight circumstances.
